🔗 Share this article

Given that the United States continues making unprecedented revisions to its vaccination schedules, a particular individual has emerged in a surprising turn: Høeg, a US-based sports medicine doctor and epidemiologist who rose to prominence by questioning COVID-19 vaccinations throughout the global health crisis and has concentrated on possible deaths following Covid immunization in her brief tenure at the US Food and Drug Administration (FDA).

Planned Overhauls to Pediatric Immunization Schedule

Public health authorities planned to announce major changes to the childhood vaccination calendar in December, synchronizing the US with Denmark’s immunization schedule, according to reports – a substantial departure that would place the US out of alignment with much of the international standard with insufficient data for public health gain. The announcement has been pushed back until the new year.

Rather than the director of the vaccine center, Høeg is scheduled to speak at the meeting. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to lead the division this year.

Consolidating Power at the FDA

Høeg's temporary position may indicate a tighter collaboration between the drug and vaccine divisions as Høeg and Dr. Prasad consolidate power at the regulatory agency – and it points to a renewed priority upon dismantling previously authorized immunizations at the FDA.

Høeg has frequently advocated for discontinuing certain childhood immunization guidelines in the US so as to align more similar to Denmark, a nation with comprehensive healthcare and a citizenry roughly the population of Wisconsin’s.

So far comments, she has kept her attention on vaccines – usually the purview of Dr. Prasad, chief of the FDA’s vaccine center – as opposed to drug regulation.

Questions Over Qualifications

The appointee has no obvious background in drug development, oversight or leadership, which has been customary for past leaders of the biologics center. She has been employed at the FDA as a senior adviser to the agency head and the vaccine center since earlier this year.

“It seems she lacks to have the necessary background” for leading the drug-regulation department, stated a neurologist and psychiatrist. “She has not conducted a scientific study. She lacks experience in running a sizeable institution. She lacks background in pharmaceutical oversight.”

Past commissioners of CBER would “understand regulatory frameworks and the research of pharmaceutical innovation”, said Dr. Janet Woodcock. “Frankly, she doesn’t have the type of experience that previous people who led the center have had.”

The drug center has an vast workload at the FDA, she emphasized.

“Many people just pays attention on the innovative therapies, but the generic drug division clears a multitude of generic drugs. There is also a biosimilars program, over-the-counter program and other areas, and all of those must be managed,” Woodcock noted. “The thing you overlook, that is the part that I always told people is going to bite you.”

There is also, a substantial leadership aspect to the position, which supervises in excess of 5,000 personnel. “It is a enormous management job, if you perform it correctly,” she said.

Response and Controversial Policies

When asked about questions about Dr. Høeg's qualifications and whether this appointment indicates increased cooperation among FDA leaders on vaccines, a representative stated that the “concerns rely on flawed premises”.

“Her experience is consistent with the functions of her job,” the official said, citing the period Høeg spent guiding the FDA commissioner on “medication safety and regulatory science, including computational safety modeling and shot safety tracking”.

In her interim role, Høeg assumes responsibility for the commissioner’s new fast-track approval initiative, a controversial expedited therapy clearance system that reportedly concerned her predecessors. “By what process are these medications being selected for this voucher program? Who takes the decisions?” Howard said. “There’s a lot of confidentiality occurring at the agency right now.”

Broadly speaking, he remarked, “the FDA appears to be shifting towards laxer rules of pharmaceuticals, except for shots.”

Public History on Immunizations

Regarding immunizations, Høeg has a more established, if troubling, past, some experts have noted. She released a study using non-validated crowd-sourced reports to determine the incidence of heart inflammation after Covid immunization. She counseled the state of Florida chief medical officer Joseph Ladapo, who reportedly have modified findings to suggest Covid vaccines are pose a greater threat than they are.

Included in her “policy goals” for the current government featured changing guidelines for new vaccines and ending “optional” vaccines, she stated after the election on a audio program. At the FDA, Dr. Høeg has according to sources floated the idea of barring adolescent males from getting COVID-19 vaccines.

“She is an thorough ideologue who starts off with her conclusions and reverse-engineers to accommodate the science in a highly deceptive, dishonest manner,” Dr. Howard argued.

Gaining Influence and a “Revenge Tour”

Dr. Høeg joined fellow skeptics, {like|